Physician profile
Maan A Askar
NPI 1053321117
$4,846.99
in general payments reported to CMS, 2019-2025
29 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $406 · 2021: $282 · 2022: $242 · 2023: $407 · 2024: $1,394 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,002.39 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.66 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $651.18 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $440.97 | 2019-2025 | |
| Abbott Laboratories | $333.25 | 2021-2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $321.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $263.60 | 2024 | Voquezna |
| Lilly USA, LLC | $253.60 | 2024 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $241.88 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.70 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $202.97 | 2019-2020 | |
| Amgen INC. | $182.72 | 2024 | Repatha, Otezla |
| Exact Sciences Corporation | $170.49 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $151.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $126.20 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.00 | 2019-2025 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| The Binding Site INC. | $106.75 | 2023 | Freelite |
| Bsn Medical INC | $72.38 | 2025 | |
| Becton, Dickinson and Company | $63.87 | 2019-2020 | |
| Verona Pharma, INC. | $52.03 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $34.97 | 2019 | |
| Astellas Pharma US INC | $28.80 | 2020 | |
| Circassia INC. | $27.37 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.96 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $17.55 | 2025 | Eliquis |
| Shield Therapeutics INC | $17.01 | 2024 | |
| Abbvie INC. | $14.08 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.78 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maan Askar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.